



Blazing the trail for innovative tuberculosis diagnostics

Seda Yerlikaya¹ · Tobias Broger¹ · Chris Isaacs² · David Bell³ · Lydia Holtgrewe¹ · Ankur Gupta-Wright^{1,4} · Payam Nahid⁵ · Adithya Cattamanchi^{5,7} · Claudia M. Denking^{1,6}

Received: 21 August 2023 / Accepted: 1 November 2023 / Published online: 30 November 2023
© The Author(s) 2023

Abstract

The COVID-19 pandemic brought diagnostics into the spotlight in an unprecedented way not only for case management but also for population health, surveillance, and monitoring. The industry saw notable levels of investment and accelerated research which sparked a wave of innovation. Simple non-invasive sampling methods such as nasal swabs have become widely used in settings ranging from tertiary hospitals to the community. Self-testing has also been adopted as standard practice using not only conventional lateral flow tests but novel and affordable point-of-care molecular diagnostics. The use of new technologies, including artificial intelligence-based diagnostics, have rapidly expanded in the clinical setting. The capacity for next-generation sequencing and acceptance of digital health has significantly increased. However, 4 years after the pandemic started, the market for SARS-CoV-2 tests is saturated, and developers may benefit from leveraging their innovations for other diseases; tuberculosis (TB) is a worthwhile portfolio expansion for diagnostics developers given the extremely high disease burden, supportive environment from not-for-profit initiatives and governments, and the urgent need to overcome the long-standing dearth of innovation in the TB diagnostics field. In exchange, the current challenges in TB detection may be resolved by adopting enhanced swab-based molecular methods, instrument-based, higher sensitivity antigen detection technologies, and/or artificial intelligence-based digital health technologies developed for COVID-19. The aim of this article is to review how such innovative approaches for COVID-19 diagnosis can be applied to TB to have a comparable impact.

Keywords Diagnostics · Tuberculosis · COVID-19 · Innovation · Technology

Introduction

“Squarely put, the drugs are in the north and the disease is in the south,” stated the former World Health Organization (WHO) director general Gro Harlem Brundtland in response to the AIDS epidemic in the late 1990s [1]. The same principle still holds true for innovative tools from drugs to diagnostics today. The COVID-19 pandemic exposed the strengths and weaknesses of the present research and development (R&D) system. While R&D progressed at an unparalleled rate, access to its products outside of the global north and novel technology usage for diseases associated with poverty primarily affecting the global south have remained restricted. One of these diseases, tuberculosis (TB), stands to gain significantly from the diagnostic industry’s surge of innovation brought on by the pandemic. In this review, we explore how the cutting-edge solutions created for COVID-19 diagnosis may be applied to TB to truly impact how TB is diagnosed.

✉ Seda Yerlikaya
seda.yerlikaya@uni-heidelberg.de

- ¹ Division of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, Heidelberg, Germany
- ² Connected Diagnostics Limited, London, UK
- ³ Independent Consultant, Lake Jackson, TX, USA
- ⁴ Institute for Global Health, University College London, London, UK
- ⁵ UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA
- ⁶ German Centre for Infection Research, Partner Site Heidelberg University Hospital, Heidelberg, Germany
- ⁷ Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, CA, USA

COVID-19: a new era in diagnostics

Unprecedented speed and money

In the early stages of the pandemic, WHO established access to the COVID-19 Tools Accelerator (ACT-A) partnership [2] with a budget of \$1.5 billion USD (all dollar amounts are given in USD hereafter) [3] for its diagnostic pillar. In the United States (US) alone, the National Institutes of Health (NIH) allocated more than \$1.5 billion to the Rapid Acceleration of Diagnostics (RADx[®]) initiative [4–6]. The large investments and sizeable market prospects led to expedited diagnostic research and a surge of innovation. Three months after COVID-19 was declared a pandemic, WHO listed the first two molecular assays for emergency use [7]. As of October 15, 2023, FIND, the global alliance for diagnostics, COVID-19 Test Directory lists 2195 tests including laboratory, point-of-care (POC), and at-home/over-the-counter (OTC) tests, while the Johns Hopkins Centre for Health Security Antigen and Molecular-based Tests Tracker lists 208 commercial and 143 laboratory-developed tests (as of March 30, 2022) [8, 9].

The best of innovation: new sampling methods and testing technologies

COVID-19 diagnostic test development does not only stand out for its sheer number of tests but also for versatility in terms of targets, sample types, and operational characteristics. Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) on isolated RNA from nasopharyngeal (NP) specimens has been the gold standard for SARS-CoV-2 detection since the beginning of the pandemic; however, the variety of samples and tests expanded quickly in response to the need for effective and practical testing in many contexts and situations. NP swabs were the sample of choice despite sputum having higher average viral load levels because not all patients can produce sputum [10, 11]. Several swab types (e.g., nylon flocked swabs) and swab samples (e.g., NP, oropharyngeal, and nasal swabs) have been evaluated for SARS-CoV-2 detection to optimize sample collection and processing for follow-up molecular or antigen testing [10, 11].

The number and variety of fully-integrated, cartridge-based, rapid molecular platforms that use swabs for sampling has also increased dramatically for COVID-19. As of October 15, 2023, the FIND test tracker includes 34 such commercial tests from 27 companies [8]. The majority of these tests require minimal sample preparation, operate on portable or easily transportable equipment, and provide results during a single clinical visit (within two hours of

sample collection) [12]. Reverse transcription loop-mediated isothermal nucleic acid amplification (RT-LAMP) has emerged as the method of choice among the various isothermal techniques due to its low resource requirement and relative simplicity [13]. The main contributing factor to a rise in LAMP-based diagnostics has been the expiration of Eiken Chemical's key patent on LAMP [29, 30]. The US FDA has authorized the emergency use (EUA) of 18 COVID-19 RT-LAMP-based products by 14 developers (as of October 19, 2023) [14]. Among them are at-home/OTC diagnostic tests and systems utilizing clustered regularly interspaced short palindromic repeat (CRISPR)-Cas (CRISPR-associated protein) for detection after RT-LAMP amplification. As reviewed elsewhere [15–19], CRISPR-Cas shows promise of low-cost, simple, quick, and accurate molecular tests. However, only a small number of CRISPR tests have been approved for use in Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratories [8, 14], due primarily to its subpar application for POC up to this point.

COVID-19 antigen detection tests have been used for screening and triage throughout the pandemic because they are faster, less expensive than molecular tests, and simple enough to allow for self-testing. Despite their inferior sensitivity compared to PCR, some new POC-applicable instrument-based antigen tests outperformed their conventional lateral flow counterparts [20, 21]. For instance, a systematic review and meta-analysis found the SARS-CoV-2 antigen test from UK-based LumiraDx to be the most sensitive test, with a pooled sensitivity of 82.7% (95% confidence interval [CI] 73.2–89.4%) [20]. Multiple instrument-based, fully automated, POC antigen detection platforms now have US FDA EUA [22] or Conformité Européenne (CE)-marking [8].

Breath tests could potentially detect COVID-19 earlier because volatile organic compounds (VOCs) first appear in breath during the early stages of infection [23]; however, only a few breath-based tests have been approved for clinical use [24, 25]. US-based InspectIR Systems obtained US FDA EUA for its Breathalyzer test, which uses a portable gas chromatography-mass spectrometry (GC-MS) instrument to detect five VOCs associated with SARS-CoV-2 infection in exhaled breath [24]. Additionally, the companies Deep Sensing Algorithms (DSA; Finland) and Impspec Diagnostics (UK) received CE-marking for their spectroscopic-based breath tests to determine a person's metabolic response to COVID-19 [26, 27]; however, their real-world effectiveness and applicability remain to be seen. Moreover, although still in the preclinical stages, exhaled breath aerosol (XBA) collection paired with SARS-CoV-2 molecular detection is showing promise [28–31]. Unlike VOCs, direct nucleic acid or antigen-based pathogen detection in XBA has the potential to be highly specific and is associated with the transmission of respiratory pathogens. Although highly technical

and resource-intensive, current tools can effectively collect XBAs and detect pathogens [32]. The COVID-19 pandemic has sparked research into simpler, filter-based XBA collection devices that can be implemented in clinical settings such as face masks with embedded biosensors and blow tubes [28, 33, 34]. Simple blow tubes may offer a more scalable solution with faster sampling. A silicon chip-based sample collector for subsequent molecular detection of SARS-CoV-2 virus particles is being developed for this reason by IMEC, a Belgian R&D organization, in collaboration with industry partners [35, 36].

Putting diagnostic ownership into patients' hands: self-testing

The availability of simple, easy-to-use, rapid, and affordable diagnostics, and evidence showing that easy-to-collect samples like saliva and nasal swabs are clinically valid, has made self-testing a viable option. WHO recommended COVID-19 self-testing using rapid antigen tests as a supplemental testing approach in March 2022 [37]. Importantly, for the first time, four molecular test developers received US FDA EUA for self-testing [14]. These tests can be performed with self-collected nasal swabs using portable, battery-powered devices that return results within 20–60 min [8, 38–41]. Although technological and regulatory advancements in this area have been promising, it is still unclear how frequently and effectively molecular home tests are used.

Next-generation sequencing

Throughout the pandemic, the SARS-CoV-2 genomic surveillance relied heavily on next-generation sequencing (NGS), and when new variants of concern emerged, NGS capabilities swiftly expanded globally [42]. NGS eventually also proved useful for diagnosing the COVID-19 disease, especially when new variants emerged. FDA EUAs for SARS-CoV-2 NGS tests that may be used in CLIA-certified laboratories for diagnostic purposes have so far been granted to two products [14].

Increased use of digital health technologies: digitization

In the fight against COVID-19, digitally connected diagnostic tests have proven critical for timely case identification and public health surveillance by enabling instant and accurate patient data transmission to health management information systems, real-time monitoring of disease patterns, and assessment of operational needs. As a result, connectivity is now actively considered when developing diagnostics. In addition, the artificial intelligence (AI) community has developed patient triage and diagnosis support software with

a focus on a variety of targets, including chest X-ray (CXR) and ultrasound images, cough, and lung sounds [43–49]. However, the small size and low quality of algorithm training data and the difficulty of the regulatory pathways for such solutions have been a barrier for developers, preventing the tools from reaching clinical settings [50]. Nevertheless, the US FDA has granted EUA to three COVID-19 screening devices using machine learning [51]. Moreover, a smartphone-based cough sound app for COVID-19 screening (ResApp Health, AU) with a CE-mark and approval from the Australian Therapeutic Goods Administration (TGA) now establishes a precedent for the regulatory approval of AI-based tools for infectious disease detection [52, 53].

What about TB?

TB still claims 1.5 million lives every year, despite COVID-19 having displaced it as the world's most lethal infectious disease [54]. Delayed and absent diagnoses provide a substantial barrier to the improvement of individual TB outcomes and control. Each year, more than one-third of all cases of TB go undiagnosed. This diagnostic gap has widened due to COVID-19 [54]. Sputum smear microscopy is still the most widely used TB microbiological test, even though WHO recommends rapid molecular testing first [55]. The varying clinical performance of smear microscopy, together with the difficulties in collecting sputum from patients and access to healthcare, is one of the primary reasons for missed TB diagnosis.

To foster innovation in TB diagnostics and to link end-user demands with test targets and specifications, WHO released high-priority target product profiles (TPPs) for novel TB diagnostics in 2014 [56]. In order to address the local demands at all levels of healthcare in high-TB settings, a variety of technologies in the field of TB diagnostics are required, as reflected by the WHO TPPs (Fig. 1). Despite this, no TB test has satisfied these targets. Accelerated innovation is critically needed to ensure that novel, effective, and fit-for-purpose diagnostics reach the market and aid in the search for the “missing millions” [54, 57].

Money and investment

UN member states recognized the need for an annual TB budget of US\$ 2 billion in 2018 [58]; nonetheless, funding for TB research has not increased since then [59]. Moreover, the amount of money spent globally on TB research remained at US\$ 915 million in 2020, falling short of even half of the UN target or the total budget for the ACT-A diagnostics pillar [54]. In reality, it is estimated that in the next 2 years, about US\$10 billion will be required, US\$ 613 million of which will go towards diagnostics research [59].




Fig. 1 A summary of TB diagnostic needs along the care cascade (adapted from 160 with author permission). *DST* drug-susceptibility testing. Figure created with BioRender.com

Globally, an estimated 10.6 million people fell sick with TB in 2021, nearly 90% live in 30 high TB burden countries, all of which are LMICs [54]. An analysis of the smear-replacement market from 2014 pegged the market's size at 30.8 million tests, with a potential annual market value of US\$ 154 million, assuming a US\$ 5-unit cost [60]. This estimate only considers the initial diagnosis; non-sputum, biomarker-based tests, screening or drug susceptibility testing are not included. In addition, Kik et al. conducted a thorough analysis to estimate the market potential of a non-sputum-based biomarker test for the high-burden countries of South Africa, Brazil, China, and India, and they estimated a potential value of US\$ 56–84 million and 14 million tests for these four countries [61–64]. The market for non-sputum, biomarker-based tests is predicted to reach US\$ 406 million by 2026, growing at a compound annual growth rate (CAGR) of about 6%, applying the same assumptions across all LMICs. Moreover, in high-burden countries, TB diagnostics are purchased for the public healthcare sector through national health ministries, which are financially backed by global health donors; however, there is also a sizable private healthcare sector that requires TB diagnostics, aside from the heavily involved public sector.

Despite this market potential, companies steer clear of the TB diagnostics sector, fearing substantial opportunity costs associated with prioritizing products for the LMIC market. Nonetheless, it is worthwhile to consider that any developer is likely to benefit from economies of scale by producing low-margin, but high-volume products and expanding its portfolio, as Cepheid did in the case of GeneXpert Dx System (Cepheid, CA, USA) GeneXpert System. Besides, some of the countries with high TB burden are emerging markets [65]. Moreover, several clinical platforming initiatives offer developers in-kind contributions, reducing development costs and accelerating time to market. Through its 'Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB)' program, the NIH is currently funding three

such initiatives; ENDxTB (<http://www.endxtb.com>), R2D2 TB Network (<http://www.r2d2tbnetwork.org>), and FEND-TB (<http://www.fend-tb.org>) [66]. Additionally, global organizations like FIND and Stop TB Partnership provide developers interested in neglected, poverty-related diseases with ongoing support and guidance for development, validation, and scale-up [67, 68]. These resources provide diagnostic developers, including academic groups, start-ups, and companies, with access to clinical samples and clinical evaluations for TB diagnostic technologies at any stage of development. Such initiatives are likely to continue. For instance, the Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) project, recently funded by the US Agency for International Development (USAID), intends to support the next step toward large-scale implementation of innovative tools [69].

To ensure a sustainable supply of diagnostics in settings of need, it is crucial to leverage such initiatives to also advance local R&D and manufacturing in LMICs, as demonstrated for COVID-19 with the IPD/DiaTROPix project in Senegal [70–72]. Increased collaboration between LMIC-based diagnostic developers and clinical platform networks like those mentioned above, as well as with international groups like FIND and the Stop TB Partnership, is likely to give them the support they need to enter the global diagnostics scene and eventually reduce reliance on high-income country-based companies for TB tests.

Challenge: the bug

The biology of SARS-CoV-2 permitted the development of rapid, POC diagnostics, but the adaptation to TB presents technical challenges. The lipid-rich cell wall of the *Mycobacterium tuberculosis* (MTB) bacterium makes chemical and enzymatic lysis methods mostly ineffective, often necessitating mechanical lysis methods like bead-beating and sonication instead. The yield and quality of genomic DNA are

consequently frequently adversely affected. Further reducing the amount of MTB genomic DNA available for subsequent molecular detection is the low bacterial load in accessible clinical samples (e.g., oral swabs). The design of PCR assays is further complicated by the high guanine/cytosine content of the MTB genome. Because of these issues, the methodologies for sample selection, bacterial lysis, nucleic acid extraction, and PCR design must be carefully considered when working with MTB.

Compared to well-defined, easily detectable viral antigens, few antigenic biomarkers have been identified for MTB, with lipoglycan lipoarabinomannan (LAM) being the most researched, most promising and conveniently accessible from an easy-to-collect sample, urine [73]. LAM is easier to detect with acceptable performance in individuals with advanced HIV in those with disseminated TB [74]. LAM, however, shows structural variations among MTB complex species and different bodily fluids [75, 76]. Additionally, current research suggests that cultured LAM is not entirely representative of LAM in patients [77], making the use of purified urinary LAM crucial for R&D.

Technical innovation: sampling

Sample type is an important consideration when applying novel technologies to TB. Sputum is the sample of choice for TB, but it is difficult to work with and challenging to collect, especially from children and people living with HIV. As a result, the R&D focuses on moving away from sputum and towards more accessible and easy-to-collect samples for TB diagnosis [56] (Fig. 2).




Fig. 2 Clinical samples and targets proposed for TB testing. Figure created with BioRender.com

Rapid, POC molecular platforms compatible with swab samples have been extremely useful for COVID-19 testing. Oral swabs have emerged as an appealing sample choice for TB testing as well. The feasibility of employing oral swabs for TB testing has already been documented in the literature [78–91]. The sensitivity of Xpert MTB/RIF Ultra (Xpert Ultra; Cepheid, CA, USA) when used with oral swabs ranged from 45% (95% CI 29–62%) to 77.8% (95% CI 64.4–88.0%) compared to a sensitivity of ~90% for sputum [80, 83, 92]. The performance discrepancies can largely be explained by the diverse swabbing and sample-handling strategies employed. For instance, the Cangelosi and Franke groups showed that tongue swabs yield stronger signals than cheek or gum swabs and that various swab brands can differ by up to two-fold in the bacterial mass they can capture [79, 85, 87]. This suggests that performance is likely to increase with swab type, collection, and storage optimization. In line with this, multiple concurrent efforts from several groups are underway to optimize and standardize the collection and handling of oral swabs for TB testing. Once an optimal sampling protocol is devised, swabs are expected to make it easier to adapt a COVID-19 test strategy to TB. Even if the sensitivity does not reach that of sputum, swab-based TB tests may reach high diagnostic yields through increased sample availability and be helpful when sputum cannot be obtained for molecular testing. Moreover, swabs collected in communities could be used for high-throughput testing with WHO-approved moderate-complexity molecular technologies, which had more installed bases during the pandemic, if the sample referral network was improved. This would facilitate the annual community-wide TB screenings, which have been shown to lower the prevalence [93]. Additionally, COVID-19 has also helped to improve swab sampling's acceptance and perception. The use of swabs for sample collection for diagnostic purposes is now commonplace among populations worldwide. This could be leveraged to increase swab uptake and acceptability as a sample for TB diagnosis.

Breath has long been an attractive diagnostic sample for TB due to its non-invasive collection and link to TB transmission. VOC-based detection in exhaled breath and condensate, which is sensitive to fluctuations in exogenous and endogenous variables, has long been the focus of breath-based testing for TB [23, 94–96]. While other VOC-based breath tests had a wide range of sensitivity (62% to 100%) and specificity (11% to 84%), electronic nose tests were reported to have an estimated summary sensitivity and specificity of 92% (95% CI 82–97%) and 93% (95% CI 88–96%), respectively [97]; however, clinical use of breath-based TB testing has not yet reached its full potential. The main barrier to its introduction into clinical settings and broad use has been the lack of standardization of breath samples and analysis, which results in high test performance variability [95]. The development and application of VOC-detecting

breath tests for TB may be sped up by the innovative methodologies and detecting techniques that have just hit the market during the COVID-19 period. Alternatively, XBA bears the promise of being a sensitive and highly specific diagnostic specimen due to its capacity to carry pathogens, thereby enabling pathogen detection via molecular tests [95, 98]. The key challenge to detect pathogen nucleic acids in XBA is their low abundance. Efficient aerosol collection for MTB detection has up until now required intensive technical efforts or lengthy sampling periods and has only been used in academic research. The respiratory aerosol sampling chamber (RASC), a 1.4 m³ cleanroom chamber where patients sit for XBA sampling that requires active pumping of large volumes of air, serves as an illustration of this [99]. Although TB was detected in 97% of patients after 10 min of sampling, such complex instrumentation is unsuitable for low-cost POC use. Face mask sampling and filter-bearing blow tubes, which have been suggested for COVID-19 detection, could be further developed to detect TB as more POC solutions, particularly in light of the currently available proof-of-concept data for the applicability of face mask sampling to TB [100–104].

The suitability of other sample types for TB testing (e.g., urine, blood, stool) has also been assessed. Since LAM is found in TB patients' urine, urine has been the sample of choice for antigen detection tests [105]. Although the use of urine as a sample type for molecular TB testing has also been investigated, the results show that it is less accurate than sputum-based testing, with a pooled sensitivity of 55% (95% CI 36–72%) [106]. Host blood transcriptomic TB biomarkers for diagnostic, prognostic, and treatment monitoring purposes are also being investigated [107–109]. Despite this, they are still a long way from being implemented in clinical settings due to their variable performance, as well as the high cost and complexity of the currently available detection tools [108]. Cell-free DNA (cfDNA) is another biomarker possibly found in urine and blood (cfDNA). Currently, the pooled sensitivity of cfDNA for TB diagnosis using various sample types is reported to be 68% (95% CI 52–80%) [110]; however, with optimized pre-analytical conditions and more sensitive detection methods, as seen in COVID-19, this is anticipated to improve [111–113]. Additionally, proof-of-concept for the detection of MTB cfDNA using CRISPR in both adults and children with TB has been achieved, opening the door for the use of future CRISPR-based POC solutions for TB [114]. Given the challenges in collecting sputum samples from children, WHO advised utilizing Xpert MTB/RIF (Xpert; Cepheid, CA, USA) testing of stool samples as a primary diagnostic test for TB in children presenting pulmonary TB signs and symptoms in 2020 [115]. Its application in adults has also been researched, and the pooled sensitivity of stool PCR was reported to be 89.7% (95% CI 81.4–95.9%) [116].

Technical innovation: instrumentation

Molecular testing

Since its introduction in 2010, the GeneXpert Dx System (Cepheid, CA, USA), an integrated, single-use cartridge-based diagnostic system, has been the molecular diagnostic test of preference for TB [117]. MTB DNA and mutations linked to rifampicin resistance are detected by the Xpert and Xpert Ultra cartridges, the latter of which is an upgraded model with greater sensitivity [117, 118]. The current global access price of the GeneXpert 10-color module is less than US\$ 10,000, while the Xpert and Xpert Ultra cartridges cost about US\$ 7.97 apiece, according to the Stop TB Partnership Global Drug Facility (GDF) Diagnostics, Medical Devices and Other Health Products Catalog [119]. Xpert is, nonetheless, not a true POC solution because it requires constant power, high maintenance due to high susceptibility to dust, and low operating temperatures [120]. GeneXpert Omni System (Omni), a sample-to-result molecular diagnostics system that can run all of the company's molecular diagnostic test cartridges, was introduced by Cepheid in 2015 as a genuine POC substitute. It is easy to use, portable, battery-operated, and smartphone-controlled [121]. Despite Omni's demonstrated clinical performance in independent studies [121], Cepheid recently halted Omni's development following several delays [122]. This leaves a sizable market for innovative, near-patient molecular POC solutions for TB testing.

The Truenat™ System (Molbio Diagnostics, India) is now the sole POC option for TB. Truelab™ is a chip-based micro-PCR device that can perform a 40-cycle real-time PCR in 35 min, while Trueprep® is an automated device that extracts DNA from sputum in under 20 min. Both are portable, battery-operated, and robust even in harsh environmental conditions (i.e., 40 °C, 80% relative humidity) [123, 124]. The Truenat™ MTB and MTB Plus assays for TB detection and the MTB-RIF Dx reflex assay for RIF resistance detection are three assays that may be run on Truelab™ utilizing the DNA eluate from Trueprep®. WHO recommended Truenat as an initial test for TB and rifampicin resistance detection after independent clinical trials showed that the assays have comparable accuracy to Xpert and Xpert Ultra, even when used in primary health care clinics [55]. The Stop TB Partnership supports the introduction of Truenat™ with 301 devices and 580,000 tests in countries with a high TB burden [125]. Truelab™ Uno Dx Workstation is listed as costing US\$ 10,000 in the Stop TB Partnership GDF catalog, whereas single MTB and MTB Plus tests are listed as costing US\$ 7.9 apiece [119].

Less than 40% of all notified TB patients undergo an initial rapid diagnostic test, creating a significant diagnostic gap [126]. The TB field would benefit immensely from a

variety of POC solutions employable in community or at-home settings, notwithstanding the promise of Truenat™ as a near-patient TB test. For more accessible TB diagnosis, instrument-free molecular tests compatible with such use cases are highly desirable. Once the oral swab procedures for TB testing are refined and made widely applicable by diagnostic developers, the swab-based nature of these tests makes their application to TB easier. Nevertheless, TB-related technical challenges persist. The preferred site for TB swab collection, the dorsum of the tongue, appears to have a lower bacterial load than sputum. Consequently, highly sensitive systems are needed. CRISPR could enable such higher sensitivities when combined with isothermal methods, but its POC application would require one-pot techniques and automation [127].

The COVID-19 POC tests' current price, nonetheless, is a deterrent to their adoption in LMICs; however, large-scale manufacturing spurred by promising market opportunities and bulk purchases for LMIC markets combined with a tiered pricing approach is likely to drive the test prices down, at least for high-burden settings in need. Additionally, the current WHO recommendation for the adoption of LAMP-based tests for TB would make it easier for any future LAMP tests to be prequalified and get access to the market [55]. Besides, the expansion of COVID-19 molecular platforms installed globally would facilitate the quick adoption of the newly developed TB assays for these platforms. In addition, using open source tools, such as the no-cost licenses provided by UC Berkeley and Lawrence Livermore National Lab for the best primer sets for a TB LAMP assay that they identified using a comparative genomics method, can also help to ease the adoption of LAMP-based novel testing for TB (unpublished data).

Antigen testing

The first urinary antigen detection test for TB was the Alere Determine™ TB LAM Ag test (Abbott, IL, USA), which was recommended by WHO for TB diagnosis and screening in people living with HIV [128, 129]. The test was an intriguing alternative for usage in resource-limited situations, because of its quick turnaround time (< 30 min), instrument-free operation, and minimal training requirements with its global access price at US\$ 3.70 per test [119, 130]. It was also the only commercially available non-sputum-based TB test since it detected LAM in urine; however, its adoption, even in settings with a high HIV/TB burden, remained limited due to its suboptimal performance [131]. In an effort to enhance analytical and clinical performance, Fujifilm (JP), with support and guidance from FIND, developed a new LFA called Fujifilm SILVAMP TB LAM that also detects LAM in urine and returns results in under an hour [132]. The test performance of this next-generation of LAM-based

urine tests approaches the WHO TPP for a non-sputum-based, biomarker test ($\geq 65\%$ sensitivity; $\geq 98\%$ specificity) [56, 133]. Improved performance of the test as compared to its Alere equivalent was made possible by the employment of higher affinity monoclonal antibodies and a silver-amplification phase that boosts the visibility of the test and control lines [134, 135]. The limit of detection (LoD) of a rapid, affordable POC LAM detection test that can detect TB in all patient groups and meet the WHO TPP is projected to be 5 pg/mL in comparison to the current tests' LoD of > 25 pg/mL [136]. Instrument-based, high-sensitivity antigen detection approaches, such as those utilized for COVID-19, are therefore more likely to hit this target than conventional LFAs; therefore, fully automated, instrument-based POC antigen detection tools developed for COVID-19 would be worth exploring for their performance in detecting LAM in TB patients. Moreover, well-characterized monoclonal antibodies [76, 134, 137], well-described LAM concentration ranges [136], and readily available and easily accessible biobanks [138, 139] can all be advantageous for the development of next-generation LAM tests with improved performance.

Sequencing

The right choice of TB treatment, where drug resistance is a serious issue and a factor in high morbidity and mortality, depends on the detection of clinically relevant drug-resistance genes along with the disease. Molecular and conventional culture-dependent phenotypic methods (i.e., the BD BACTEC™ MGIT™ 960 system) are currently used in drug-susceptibility testing (DST) for TB [55]; however, culture methods are labor- and time-intensive, and molecular methods can only target a limited number of genes and mutations. WHO reported a total of 196 individual clinically relevant mutations linked to resistance to 12 TB drugs in its 2021 Catalogue of mutations in MTB complex and their association with drug resistance [140]. NGS technology is anticipated to aid in addressing these challenges by enabling comprehensive, rapid DST [141]; however, the use of NGS for TB has so far been constrained by its high cost. It can, nonetheless, be envisaged that NGS-based DST for TB will prove to be cost-effective when and if it can be implemented into the current COVID-19 workflows. Additionally, the application of NGS for TB is projected to be facilitated by the COVID-19-driven expansion of global sequencing capacity, availability of qualified staff, experience in using NGS for clinical purposes, and readily-available data analysis and storage solutions [142]. It is, though, necessary to develop NGS solutions that can be applied straight from sputum (or any other clinical sample) or that are simple to plug into newly developed molecular TB diagnostics.

Digital health technologies

The use of digital technology in the field of TB diagnostics has thus far been restricted to the use of computer-aided detection (CAD) software for automatically reading and interpreting chest X-ray (CXR) images, obviating the need for expert readers (radiologists) [143, 144]. COVID-19-driven advances in digital innovation and data science have created new opportunities for better TB care. For instance, the COVID-19 pandemic has accelerated healthcare workers' digital transformation [145, 146], which can and should be extended to the TB field. Despite evidence of improved data quality and patient management when using digital records and tools, adoption of digital health technologies aimed at healthcare workers has been slow in the TB field [147], in part due to a lack of focus on making them acceptable to intended users and feasible to implement and sustain in low-resource, high-burden settings. The COVID-19 experience, however, is likely to facilitate transitioning to digital, case-based, real-time surveillance systems for TB as advocated by WHO [148]. Therefore, in the post-COVID-19 era, the need for novel TB diagnostic tests with connectivity features is greater than ever.

Building off of the COVID-19 experience, access-related barriers to TB diagnosis may also be addressed by AI-based digital solutions. In fact, several tools to detect and classify cough and lung sounds are being developed now, for applications like TB screening and triage [149–151]. Yet, despite the promise of machine learning algorithms to support clinical decision-making and improve healthcare delivery [152], there are currently no digital tools for TB to help healthcare workers in low-resource settings with patient management that use AI-based prediction models to provide a personalized clinical recommendation based on a TB risk assessment.

The demand for data, however, threatened to further fragment an already complex information landscape with multiple actors and overlapping activities including those who needed to analyze available data and those who

wanted to commercially exploit it. There remain many challenges that hamper the effective sharing, analysis and use of data for country decision-making, including the lack of any prevailing business model for sustainability. While the development and evolution of standards applicable to DHTs continue, gaps still persist in the ecosystem, such as infrastructure support and human capacity to introduce, scale up, and sustain these tools. Only if these efforts continue will the diagnostic platforms that were developed during the pandemic and included connectivity be useful for TB.

Conclusion

Early in the pandemic, the COVID-19 diagnostic market was flooded with technologies because of lucrative funding possibilities and alluring market prospects; however, the market is now saturated. The decision of an increasing number of companies to reduce workforces and close facilities is a reflection of a drop in the demand for COVID-19 testing [153, 154]. The developers, funders, and most crucially the patients in need would all benefit more if the existing potential was directed on diseases like TB where there is a significant need for novel diagnostic tools.

The search for a “key” that unlocks all the doors to the diagnostic conundrum of TB has long been a focus in this field (155, 156). The long-sought solution was initially believed to be Xpert, then Omni; however, the failure of such bets on individual technologies to address all needs for controlling or preventing the complex medical and socio-economic challenges caused by TB should be clear by this point. Instead, a variety of diagnostic possibilities embedded in clinical algorithms are necessary in order to meet local needs in high TB burden settings. With the breadth and variety of technological innovation sparked by the pandemic, COVID-19 presents a unique opportunity in this regard (Fig. 3). Political will and similar investments are required to encourage developers' interest in the LMIC sector, which is the primary market for TB diagnostics. Long-term success




Fig. 3 Today and future of TB diagnostics (Dx). IS6110: insertion sequence 6110; IS1081: insertion sequence 1081; DST drug-susceptibility testing, NGS next-generation sequencing, LFA lateral flow

assay, LAM lipoarabinomannan, CAD computer-aided detection, POCUS point-of-care ultrasound. Figure created with BioRender.com

in the TB diagnostics field will also depend on funding local R&D and production and knowledge transfer to LMIC to guarantee a sustainable supply of TB diagnostics.

Author contributions SY developed the manuscript. TB, CI, DB, AG, PN, AC, LH and CD provided critical editing and review.

Funding Open Access funding enabled and organized by Projekt DEAL. This work is funded by the National Institutes of Health (NIH) (funding reference number U01AI152087; Rapid Research in Diagnostics Development for Tuberculosis Network).

Declarations

Conflict of interest Authors declare no financial conflict of interest. P.N., A.C., and C.D. are the principal investigators of the R2D2 TB Network. S.Y., T.B., C.I. and D.B., A.G. are consultants or staff of the R2D2 TB Network. T.B. holds patents in the fields of LAM detection and aerosol collection, and is a shareholder of Avelo Ltd, a Swiss diagnostics company. C.I. is the founder and director of Connected Diagnostics Limited, a UK-based commercial entity that assists companies with the development of diagnostic devices. D.B. is the chief medical officer of Hemex Health, a diagnostics development company, and consults for other diagnostic entities.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Gellman B. A turning point that left millions behind. Washington post. 2000. <https://www.washingtonpost.com/archive/politics/2000/12/28/a-turning-point-that-left-millions-behind/afe238d9-49a6-4b03-bfff-2ba83c0c4cd7/>. Accessed 17 Aug 2022.
- The Access to COVID-19 Tools (ACT) Accelerator. <https://www.who.int/initiatives/act-accelerator>. Accessed 14 Aug 2022.

3. Access to COVID-19 tools funding commitment tracker. <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>. Accessed 14 Aug 2022.
4. National Institutes of Health (NIH). RADx. <https://www.nih.gov/research-training/medical-research-initiatives/radx>. Accessed 17 Aug 2022.
5. National Institutes of Health (NIH). RADx programs. 2020. <https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs>. Accessed 30 Aug 2022.
6. Tromberg BJ, Schwetz TA, Pérez-Stable EJ, Hodes RJ, Woychik RP, Bright RA, et al. Rapid scaling up of Covid-19 diagnostic testing in the United States—the NIH RADx initiative. *N Engl J Med*. 2020;383:1071–7.
7. WHO lists two COVID-19 tests for emergency use. <https://www.who.int/news/item/07-04-2020-who-lists-two-covid-19-tests-for-emergency-use>. Accessed 14 Aug 2022.
8. Test directory—FIND. <https://www.finddx.org/covid-19/test-directory/>. Accessed 14 Aug 2022.
9. Administrator J website. COVID-19 Testing Toolkit. Antigen and molecular tests for COVID-19. <https://www.centerforhealthsecurity.org/covid-19TestingToolkit/molecular-based-tests/current-molecular-and-antigen-tests.html>. Accessed 14 Aug 2022.
10. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71:793–8.
11. Yang Y, Yang M, Yuan J, Wang F, Wang Z, Li J, et al. Laboratory diagnosis and monitoring the viral shedding of SARS-CoV-2 infection. *Innovation*. 2020;1:100061.
12. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*. 2020;2020:CD013705.
13. Khan P, Aufdembrink LM, Engelhart AE. Isothermal SARS-CoV-2 diagnostics: tools for enabling distributed pandemic testing as a means of supporting safe reopenings. *ACS Synth Biol*. 2020;9:2861–80.
14. Health C for D and R. In vitro diagnostics EUAs—molecular diagnostic tests for SARS-CoV-2. FDA. 2022. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2>. Accessed 14 Aug 2022.
15. Aman R, Mahas A, Mahfouz M. Nucleic acid detection using CRISPR/Cas biosensing technologies. *ACS Synth Biol*. 2020;9:1226–33.
16. Yuan M, Ding R, Chen S, Duan G. Advances in field detection based on CRISPR/Cas System. *ACS Synth Biol*. 2021;10:2824–32.
17. Chen B, Li Y, Xu F, Yang X. Powerful CRISPR-based biosensing techniques and their integration with microfluidic platforms. *Front Bioeng Biotechnol*. 2022. <https://doi.org/10.3389/fbioe.2022.851712>.
18. Kostyusheva A, Brezgin S, Babin Y, Vasilyeva I, Glebe D, Kostyushev D, et al. CRISPR-Cas systems for diagnosing infectious diseases. *Methods*. 2022;1:431–46.
19. Verma MK, Roychowdhury S, Sahu BD, Mishra A, Sethi KK. CRISPR-based point-of-care diagnostics incorporating Cas9, Cas12, and Cas13 enzymes advanced for SARS-CoV-2 detection. *J Biochem Mol Toxicol*. 2022;36:e23113. <https://doi.org/10.1002/jbt.23113>.
20. Brümmer LE, Katzenschlager S, McGrath S, Schmitz S, Gaedert M, Erdmann C, et al. Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta-regression analyzing influencing factors. *PLoS Med*. 2022;19:e1004011.
21. Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*. 2022. <https://doi.org/10.1002/14651858.CD013705.pub3/full>.
22. Health C for D and R. In vitro diagnostics EUAs—antigen diagnostic tests for SARS-CoV-2. FDA. 2022. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2>. Accessed 15 Aug 2022.
23. Berna AZ, Odom John AR. Breath metabolites to diagnose infection. *Clin Chem*. 2022;68:43–51.
24. Health C for D and R. In vitro diagnostics EUAs—other tests for SARS-CoV-2. FDA. 2022. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-other-tests-sars-cov-2>. Accessed 15 Aug 2022.
25. 360Dx. First FDA EUA for breath-based COVID test in hand, InspectIR focusing on commercialization. 2022. <https://www.360dx.com/covid-19/first-fda-eua-breath-based-covid-test-hand-inspectir-focusing-commercialization>. Accessed 15 Aug 2022.
26. 360Dx. Finland-based deep sensing algorithms works to commercialize COVID-19 breath test after CE marking. 2022. <https://www.360dx.com/covid-19/finland-based-deep-sensing-algorithms-works-commercialize-covid-19-breath-test-after-ce>. Accessed 15 Aug 2022.
27. 360Dx. Imspex gains CE-IVD Mark for COVID-19 breath test. 2022. <https://www.360dx.com/point-care-testing/impex-gains-ce-ivd-mark-covid-19-breath-test>. Accessed 24 Aug 2022.
28. Stakenborg T, Raymenants J, Taher A, Marchal E, Verbruggen B, Roth S, et al. Molecular detection of SARS-CoV-2 in exhaled breath at the point-of-need. *Biosens Bioelectron*. 2022;30:114663.
29. Williams CM, Pan D, Decker J, Wisniewska A, Fletcher E, Sze S, et al. Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalized patients with COVID-19. *J Infect*. 2021;82:253–9.
30. Gutmann D, Scheuch G, Lehmkuhler T, Herrlich LS, Landeis A, Hutter M, et al. Aerosol measurement identifies SARS-CoV-2 PCR positive adults compared with healthy controls. *Environ Res*. 2023;1:114417.
31. Xue Q, Kan X, Pan Z, Li Z, Pan W, Zhou F, et al. An intelligent face mask integrated with high density conductive nanowire array for directly exhaled coronavirus aerosols screening. *Biosens Bioelectron*. 2021;3:113286.
32. Mainelis G. Bioaerosol sampling: classical approaches, advances, and perspectives. *Aerosol Sci Technol*. 2020;54:496–519.
33. Nguyen PQ, Soenksen LR, Donghia NM, Angenent-Mari NM, de Puig H, Huang A, et al. Wearable materials with embedded synthetic biology sensors for biomolecule detection. *Nat Biotechnol*. 2021;28:1–9.
34. Xue Q, Kan X, Pan Z, Li Z, Pan W, Zhou F, et al. An intelligent face mask integrated with high density conductive nanowire array for directly exhaled coronavirus aerosols screening. *Biosens Bioelectron*. 2021;15:113286.
35. 360Dx. Imedc preparing breath test for SARS-CoV-2. 2020. <https://www.360dx.com/molecular-diagnostics/imec-preparing-breath-test-sars-cov-2>. Accessed 13 Apr 2023.
36. Imedc begins developing SARS-CoV-2 test to identify positive cases and confirm whether someone is contagious in less than five minutes | imec. <https://www.imec-int.com/en/press/imec-begins-developing-sars-cov-2-test-identify-positive-cases-and-confirm-whether-someone>. Accessed 13 Apr 2023.
37. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing. <https://www.who.int/publicatio>

- ns-detail-redirect/WHO-2019-nCoV-Ag-RDTs-Self_testing-2022.1. Accessed 14 Aug 2022.
38. Lucira Health | COVID-19 PCR quality at-home test. <https://www.lucirahealth.com/>. Accessed 1 Sep 2022.
 39. 360Dx. Lucira health nabs OTC EUA for SARS-CoV-2 test, expects Q1 revenues of up to \$4.5M. 2021. <https://www.360dx.com/regulatory-news-fda-approvals/lucira-health-nabs-otc-eua-sars-cov-2-test-expects-q1-revenues-45m>. Accessed 14 Aug 2022.
 40. 360Dx. Cue health over-the-counter COVID-19 test gets FDA emergency use authorization. 2021. <https://www.360dx.com/pcr/cue-health-over-counter-covid-19-test-gets-fda-emergency-use-authorization>. Accessed 14 Aug 2022.
 41. Detect. Products. <https://detect.com/our-test>. Accessed 1 Sep 2022.
 42. NGS capacity mapping—FIND. <https://www.finddx.org/sequencing/ngs-capacity-mapping/>. Accessed 31 May 2022.
 43. Jia LL, Zhao JX, Pan NN, Shi LY, Zhao LP, Tian JH, et al. Artificial intelligence model on chest imaging to diagnose COVID-19 and other pneumonias: a systematic review and meta-analysis. *Eur J Radiol Open*. 2022;18:100438.
 44. Ali H, Shah Z. Combating COVID-19 using generative adversarial networks and artificial intelligence for medical images: scoping review. *JMIR Med Inform*. 2022;10:e37365.
 45. Chandrasekar KS. Exploring the deep-learning techniques in detecting the presence of coronavirus in the chest X-Ray images: a comprehensive review. *Arch Comput Methods Eng State Art Rev*. 2022;23:1–15.
 46. Mulrenan C, Rhode K, Fischer BM. A literature review on the use of artificial intelligence for the diagnosis of COVID-19 on CT and chest X-ray. *Diagn Basel Switz*. 2022;12:869.
 47. Wang J, Yang X, Zhou B, Sohn JJ, Zhou J, Jacob JT, et al. Review of machine learning in lung ultrasound in COVID-19 pandemic. *J Imaging*. 2022;8:65.
 48. Coppock H, Jones L, Kiskin I, Schuller B. COVID-19 detection from audio: seven grains of salt. *Lancet Digit Health*. 2021;3:e537–8.
 49. Vasudevan RS, Horiuchi Y, Torriani FJ, Cotter B, Maisel SM, Dadwal SS, et al. Persistent value of the stethoscope in the age of COVID-19. *Am J Med*. 2020;133:1143–50.
 50. Aristidou A, Jena R, Topol EJ. Bridging the chasm between AI and clinical implementation. *Lancet*. 2022;399:620.
 51. Health C for D and R. Other Medical Device EUAs. FDA. 2021. <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/other-medical-device-euas>. Accessed 19 Aug 2022.
 52. Benjamins S, Dhunoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. *NPJ Digit Med*. 2020;3:118.
 53. Khanzada A, Hegde S, Sreeram S, Bower G, Wang W, Mediratta RP, et al. Challenges and opportunities in deploying COVID-19 cough AI systems. *J Voice*. 2021;35:811–2.
 54. Global Tuberculosis Report 2022. 2022. <https://www.who.int/publications-detail-redirect/9789240061729>. Accessed 27 Oct 2022.
 55. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis—rapid diagnostics for tuberculosis detection 2021 update. 2021. <https://www.who.int/publications-detail-redirect/9789240029415>. Accessed 30 Jul 2021.
 56. WHO High-priority target product profiles for new tuberculosis diagnostics. World Health Organization. 2014. http://www.who.int/tb/publications/tpg_report/en/. Accessed 15 Mar 2021.
 57. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: the lancet commission on tuberculosis. *Lancet*. 2019;393:1331–84.
 58. UN General Assembly High-Level Meeting on Ending TB. Available from: <https://www.who.int/news-room/events/un-general-assembly-high-level-meeting-on-ending-tb>. Accessed 14 Aug 2022.
 59. 2021 Report on TB Research Funding Trends. Treatment action group. <https://www.treatmentactiongroup.org/resources/tbrd-report/tbrd-report-2021/>. Accessed 14 Aug 2022.
 60. Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? *Eur Respir J*. 2014;43:1793–6.
 61. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in Brazil in 2012. *PLoS ONE*. 2014;9:e104105.
 62. TB Diagnostics Market Analysis. Market assessment of tuberculosis diagnostics in South Africa, 2012–2013. *Int J Tuberc Lung Dis*. 2015;19:216–22.
 63. Maheshwari P, Chauhan K, Kadam R, Pujani A, Kaur M, Chitalia M, et al. Market assessment of tuberculosis diagnostics in India in 2013. *Int J Tuberc Lung Dis*. 2016;20:304–13.
 64. Zhao YL, Pang Y, Xia H, Du X, Chin D, Huan ST, et al. Market assessment of tuberculosis diagnostics in China in 2012. *Int J Tuberc Lung Dis*. 2016;20:295–303.
 65. Emerging Countries 2022. <https://worldpopulationreview.com/country-rankings/emerging-countries>. Accessed 1 Sep 2022.
 66. FEND for TB | NIH: National Institute of Allergy and Infectious Diseases. <https://www.niaid.nih.gov/research/fend-tb>. Accessed 14 Aug 2022.
 67. Stop TB Partnership. <https://www.stoptb.org/>. Accessed 19 Aug 2022.
 68. FIND. Home. <https://www.finddx.org/>. Accessed 19 Aug 2022.
 69. USAID Announces up to \$200 Million for Research to Combat Tuberculosis | Press Release | U.S. agency for international development. 2022. <https://www.usaid.gov/news-information/press-releases/aug-04-2022-usaid-announces-200-million-research-combat-tuberculosis>. Accessed 14 Aug 2022.
 70. Médecins Sans Frontières Access Campaign. Local diagnostics to meet local health needs. 2021. <https://msfaccess.org/improve-local-production-diagnostics>. Accessed 10 Aug 2021.
 71. Bigio J, van Gemert W, Kaiser B, Waning B, Pai M. Asia emerges as a hotbed of diagnostic innovations for tuberculosis. *J Clin Tuberc Mycobact Dis*. 2021;25:100267.
 72. Mérieux Foundation. Inauguration of the diaTROPIX production platform at the institut pasteur of dakar. 2013. <https://www.fondation-merieux.org/en/news/inauguration-of-the-diatropix-production-platform-at-the-institut-pasteur-of-dakar/>. Accessed 1 Sep 2022.
 73. MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM. A systematic review of biomarkers to detect active tuberculosis. *Nat Microbiol*. 2019;4:748–58.
 74. Kerkhoff AD, Sossen B, Schutz C, Reipold EI, Trollip A, Moreau E, et al. Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV. *Eur Respir J*. 2020. <https://doi.org/10.1183/13993003.01259-2019>.
 75. Flores J, Cancino JC, Chavez-Galan L. Lipoarabinomannan as a point-of-care assay for diagnosis of tuberculosis: how far are we to use it? *Front Microbiol*. 2021;15:638047.
 76. Corrigan DT, Ishida E, Chatterjee D, Lowary TL, Achkar JM. Monoclonal antibodies to lipoarabinomannan/arabinomannan—characteristics and implications for tuberculosis research and diagnostics. *Trends Microbiol*. 2023;31:22–35.
 77. Cantera JL, Rashid AA, Lillis LL, Peck RB, Drain PK, Pinter A, et al. Isolation and purification of lipoarabinomannan from urine of adults with active tuberculosis. *bioRxiv*. 2021. <https://doi.org/10.1101/2021.03.24.436904v1>.

78. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, et al. Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. *Sci Rep*. 2015;5:8668.
79. Luabeya A, Wood R, Shenje J, Filander E, Ontong C, Mabwe S, et al. Noninvasive detection of tuberculosis by oral swab analysis. *J Clin Microbiol*. 2019;57:10.
80. Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, et al. Mycobacterium tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. *BMC Res Notes*. 2019;12:349.
81. Nicol MP, Wood RC, Workman L, Prins M, Whitman C, Ghebrekristos Y, et al. Microbiological diagnosis of pulmonary tuberculosis in children by oral swab polymerase chain reaction. *Sci Rep*. 2019;9:10789.
82. Deviaene M, Weigel KM, Wood RC, Luabeya AKK, Jones-Engel L, Hatherill M, et al. Sample adequacy controls for infectious disease diagnosis by oral swabbing. *PLoS ONE*. 2020;15:e0241542.
83. Lima F, Santos AS, Oliveira RD, Silva CCR, Gonçalves CCM, Andrews JR, et al. Oral swab testing by Xpert® MTB/RIF Ultra for mass tuberculosis screening in prisons. *J Clin Tuberc Mycobact Dis*. 2020;4:100148.
84. Mesman AW, Calderon RI, Pollock NR, Soto M, Mendoza M, Coit J, et al. Molecular detection of Mycobacterium tuberculosis from buccal swabs among adult in Peru. *Sci Rep*. 2020;17:22231.
85. Molina-Moya B, Ciobanu N, Hernandez M, Prat-Aymerich C, Crudu V, Adams ER, et al. Molecular detection of mycobacterium tuberculosis in oral mucosa from patients with presumptive tuberculosis. *J Clin Med*. 2020;9:4124.
86. Song Y, Ma Y, Liu R, Shang Y, Ma L, Huo F, et al. Diagnostic yield of oral swab testing by TB-LAMP for diagnosis of pulmonary tuberculosis. *Infect Drug Resist*. 2021;12:89–95.
87. Wood RC, Andama A, Hermansky G, Burkot S, Asege L, Job M, et al. Characterization of oral swab samples for diagnosis of pulmonary tuberculosis. *PLoS ONE*. 2021;16:e0251422.
88. Andama A, Whitman GR, Crowder R, Reza TF, Jaganath D, Mulondo J, et al. Accuracy of tongue swab testing using Xpert MTB-RIF ultra for tuberculosis diagnosis. *J Clin Microbiol*. 2022;60:e00421–e422.
89. Cox H, Workman L, Bateman L, Franckling-Smith Z, Prins M, Luiz J, et al. Oral swabs tested with Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in children: a diagnostic accuracy study. *Clin Infect Dis*. 2022;75:2145–52.
90. LaCourse SM, Seko E, Wood R, Bundi W, Ouma GS, Agaya J, et al. Diagnostic performance of oral swabs for non-sputum based TB diagnosis in a TB/HIV endemic setting. *PLoS ONE*. 2022;17:e0262123.
91. Shapiro AE, Olson AM, Kidoguchi L, Niu X, Ngcobo Z, Magcaba ZP, et al. Complementary nonsputum diagnostic testing for tuberculosis in people with HIV using oral swab PCR and urine lipoarabinomannan detection. *J Clin Microbiol*. 2022;60:e0043122.
92. Andama A, Whitman GR, Crowder R, Reza TF, Jaganath D, Mulondo J, et al. Accuracy of tongue swab testing using Xpert MTB-RIF Ultra for tuberculosis diagnosis. *MedRxiv*. 2022. <https://doi.org/10.1101/2022.02.17.22271147v1>.
93. Marks GB, Nguyen NV, Nguyen PTB, Nguyen TA, Nguyen HB, Tran KH, et al. Community-wide screening for tuberculosis in a high-prevalence setting. *New England J Med*. 2019;381:1347–57.
94. Pham YL, Beauchamp J. Breath biomarkers in diagnostic applications. *Mol Basel Switz*. 2021;26:5514.
95. Wallace MAG, Pleil JD. Evolution of clinical and environmental health applications of exhaled breath research: review of methods and instrumentation for gas-phase, condensate, and aerosols. *Anal Chim Acta*. 2018;18:18–38.
96. Ghosh C, Leon A, Koshy S, Aloum O, Al-Jabawi Y, Ismail N, et al. Breath-based diagnosis of infectious diseases: a review of the current landscape. *Clin Lab Med*. 2021;41:185–202.
97. Saktiawati AMI, Putera DD, Setyawan A, Mahendradhata Y, van der Werf TS. Diagnosis of tuberculosis through breath test: a systematic review. *EBioMedicine*. 2019;8:202–14.
98. Duguid JP. The size and the duration of air-carriage of respiratory droplets and droplet-nuclei. *J Hyg*. 1946;44:471–9.
99. Patterson B, Dinkele R, Gessner S, Morrow C, Kamariza M, Bertozzi CR, et al. Sensitivity optimisation of tuberculosis bio-aerosol sampling. *PLoS ONE*. 2020;15:e0238193.
100. Williams CML, Cheah ESG, Malkin J, Patel H, Otu J, Mlaga K, et al. Face Mask sampling for the detection of Mycobacterium tuberculosis in expelled aerosols. *PLoS ONE*. 2014;9:e104921.
101. Williams CM, Abdulwhhab M, Birring SS, Kock ED, Garton NJ, Townsend E, et al. Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies. *Lancet Infect Dis*. 2020;20:607–17.
102. Williams CM, Muhammad AK, Sambou B, Bojang A, Jobe A, Daffeh GK, et al. Exhaled Mycobacterium tuberculosis predicts incident infection in household contacts. *Clin Infect Dis*. 2023;76:e957–64. <https://doi.org/10.1093/cid/ciac455>.
103. McNerney R, Wondafrash BA, Amena K, Tesfaye A, McCash EM, Murray NJ. Field test of a novel detection device for Mycobacterium tuberculosis antigen in cough. *BMC Infect Dis*. 2010;10:161.
104. Ma J, Jiang G, Ma Q, Wang H, Du M, Wang C, et al. Rapid detection of airborne protein from Mycobacterium tuberculosis using a biosensor detection system. *Analyst*. 2022. <https://pubs.rsc.org/en/content/articlelanding/2022/an/d1an02104d>. Accessed 7 Feb 2022.
105. Bulterys MA, Wagner B, Redard-Jacot M, Suresh A, Pollock NR, Moreau E, et al. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. *J Clin Med*. 2019;9:111.
106. Marangu D, Devine B, John-Stewart G. Diagnostic accuracy of nucleic acid amplification tests in urine for pulmonary tuberculosis: a meta-analysis. *Int J Tuberc Lung Dis*. 2015;19:1339–47.
107. Prospective validation of host transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR | medRxiv. 2021. <https://www.medrxiv.org/content/10.1101/2021.07.26.21260947v1?ct=>. Accessed 30 Jul 2021.
108. Hamada Y, Penn-Nicholson A, Krishnan S, Cirillo DM, Matteelli A, Wyss R, et al. Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic?—A review of evidence and the technological landscape. *eBioMedicine*. 2022;82:104174.
109. Mendelsohn SC, Mbandi SK, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Mulenga H, et al. Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. *Commun Med*. 2022;2:1–13.
110. Yu G, Shen Y, Ye B, Shi Y. Diagnostic accuracy of Mycobacterium tuberculosis cell-free DNA for tuberculosis: a systematic review and meta-analysis. *PLoS ONE*. 2021;16:e0253658.
111. Investigation of preanalytical variables impacting pathogen cell-free DNA in blood and urine | Journal of Clinical Microbiology. 2021. <https://jcm.asm.org/content/57/11/e00782-19.abstract>. Accessed 2 Feb 2021.
112. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma | Scientific reports. 2021. <https://www.nature.com/articles/srep27859>. Accessed 2 Feb 2021.
113. The art of obtaining a high yield of cell-free DNA from urine. 2021. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231058>. Accessed 2 Feb 2021.

114. Huang Z, LaCourse SM, Kay AW, Stern J, Escudero JN, Youngquist BM, et al. CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study. *Lancet Microbe*. 2022;3:e482–92.
115. WHO announces updates on new molecular assays for the diagnosis of tuberculosis and drug resistance. 2020. <https://www.who.int/news/item/13-01-2020-who-announces-updates-on-new-molecular-assays-for-the-diagnosis-of-tuberculosis-and-drug-resistance>. Accessed 19 Aug 2022.
116. Laursen LL, Dahl VN, Wejse C. Stool testing for pulmonary TB diagnosis in adults. *Int J Tuberc Lung Dis*. 2022;26:516–23.
117. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of mycobacterium tuberculosis and rifampin resistance by use of on-demand near-patient technology. *J Clin Microbiol*. 2010;48:229–37.
118. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The new Xpert MTB/RIF ultra: improving detection of mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. *mBio*. 2017;8:10.
119. GDF Product Catalog | Stop TB Partnership. <https://www.stoptb.org/global-drug-facility-gdf/gdf-product-catalog>. Accessed 19 Oct 2023.
120. Garcia-Basteiro AL, DiNardo A, Saavedra B, Silva DR, Palmero D, Gegia M, et al. Point of care diagnostics for tuberculosis. *Pulmonology*. 2018;24:73–85.
121. Georghiou SB, Alagna R, Cirillo DM, Carmona S, Ruhwald M, Schumacher SG. Equivalence of the GeneXpert system and GeneXpert omni system for tuberculosis and rifampicin resistance detection. *PLoS ONE*. 2021;16:e0261442.
122. 360Dx. Highly anticipated cepheid omni point-of-care system falls off radar. 2022. <https://www.360dx.com/molecular-diagnostics/highly-anticipated-cepheid-omni-point-of-care-system-falls-radar>. Accessed 1 Sep 2022.
123. Molbio Diagnostics Pvt. Ltd. TruelabTM Duo user manual. 2020. https://www.molbiodiagnostics.com/product_details.php?id=45. Accessed 1 Sep 2022.
124. Molbio Diagnostics Pvt. Ltd. Trueprep@AUTO v2 user manual. 2020. https://www.molbiodiagnostics.com/product_details.php?id=47. Accessed 1 Sep 2022.
125. Rapid molecular diagnostics for use at peripheral level | Stop TB Partnership. <https://www.stoptb.org/introducing-new-tools-project/rapid-molecular-diagnostics-use-peripheral-level>. Accessed 17 Aug 2022.
126. WHO standard: universal access to rapid tuberculosis diagnostics. 2023. <https://www.who.int/publications-detail-redirect/who-standard--universal-access-to-rapid-tuberculosis-diagnostics>. Accessed 20 Apr 2023.
127. Qi Y, Li K, Li Y, Guo D, Xu J, Li Y, et al. CRISPR-based diagnostics: a potential tool to address the diagnostic challenges of tuberculosis. *Pathogens*. 2022;11:1211.
128. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy guidance. <https://www.who.int/publications-detail-redirect/9789241509633>. Accessed 18 Aug 2022.
129. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV, 2019 Update. <https://www.who.int/publications-detail-redirect/9789241550604>. Accessed 18 Aug 2022.
130. Determine™ TB LAM Ag. <https://www.globalpointofcare.abbott/en/product-details/determine-tb-lam.html>. Accessed 1 Sep 2022.
131. Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. *Cochrane Database Syst Rev*. 2019. <https://doi.org/10.1002/14651858.CD011420.pub3.full>.
132. Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. *Lancet Infect Dis*. 2019;19:852–61.
133. Li Z, Tong X, Liu S, Yue J, Fan H. The value of FujiLAM in the diagnosis of tuberculosis: a systematic review and meta-analysis. *Front Public Health*. 2021;9:1892.
134. Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, et al. A novel sensitive immunoassay targeting the 5-methylthio-d-xylofuranose–lipoarabinomannan epitope meets the WHO’s performance target for tuberculosis diagnosis. *J Clin Microbiol*. 2018;56:10.
135. Mitamura K, Shimizu H, Yamazaki M, Ichikawa M, Nagai K, Katada J, et al. Clinical evaluation of highly sensitive silver amplification immunochromatography systems for rapid diagnosis of influenza. *J Virol Methods*. 2013;194:123–8.
136. Broger T, Nicol MP, Sigal GB, Gotuzzo E, Zimmer AJ, Surtie S, et al. Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. *J Clin Invest*. 2020;130:5756–64.
137. De P, Amin AG, Flores D, Simpson A, Dobos K, Chatterjee D. Structural implications of lipoarabinomannan glycans from global clinical isolates in diagnosis of Mycobacterium tuberculosis infection. *J Biol Chem*. 2021;297:101265.
138. FIND. Tuberculosis. <https://www.finddx.org/biobank-services/specimen-bank/specimens-tb/>. Accessed 1 Sep 2022.
139. R2D2 TB Network. R2D2 TB Network. <https://www.r2d2tbnetwork.org>. Accessed 17 Jan 2022.
140. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. <https://www.who.int/publications-detail-redirect/9789240028173>. Accessed 29 Aug 2022.
141. 2018—WHO—The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex technical guide. <https://apps.who.int/iris/bitstream/handle/10665/274443/WHO-CDS-TB-2018.19-eng.pdf?sequence=1&isAllowed=y>. Accessed 5 May 2021.
142. Marais G, Hardie D, Brink A. A case for investment in clinical metagenomics in low-income and middle-income countries. *Lancet Microbe*. 2023;4:e192–9.
143. Khan FA, Pande T, Tessema B, Song R, Benedetti A, Pai M, et al. Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy. *Eur Respir J*. 2017. <https://doi.org/10.1183/13993003.00953-2017>.
144. Naheyant T. AI4HLTH. AI products for tuberculosis healthcare. <https://www.ai4hlth.org>. Accessed 18 Jan 2022.
145. Budd J, Miller BS, Manning EM, Lamos V, Zhuang M, Edelstein M, et al. Digital technologies in the public-health response to COVID-19. *Nat Med*. 2020;26:1183–92.
146. Feroz AS, Khoja A, Saleem S. Equipping community health workers with digital tools for pandemic response in LMICs. *Arch Public Health*. 2021;79:1.
147. Holst C, Sukums F, Radovanovic D, Ngowi B, Noll J, Winkler AS. Sub-Saharan Africa—the new breeding ground for global digital health. *Lancet Digit Health*. 2020;2:e160–2.
148. Case-based TB surveillance. <https://www.who.int/publications/digital/global-tuberculosis-report-2021/featured-topics/case-based-surveillance>. Accessed 13 Apr 2023.
149. Pathri R, Jha S, Tandon S, GangaShetty S. Acoustic epidemiology of pulmonary tuberculosis (TB) & Covid19 leveraging explainable AI/ML. *J Pulmonol Res Rep*. 2022;4:1–6.
150. Yellapu GD, Rudraraju G, Sripada NR, Mamidgi B, Jalukuru C, Firmal P, et al. Development and clinical validation of Swaasa

- AI platform for screening and prioritization of pulmonary TB. *Sci Rep.* 2023;13:4740.
151. 2022 TB Diagnostics Pipeline Report. Treatment action group. 2022. <https://www.treatmentactiongroup.org/resources/pipeline-report/2022-pipeline-report/>. Accessed 21 Nov 2022.
 152. Lalmuanawma S, Hussain J, Chhakchhuak L. Applications of machine learning and artificial intelligence for Covid-19 (SARS-CoV-2) pandemic: a review. *Chaos Solitons Fractals.* 2020;139:110059.
 153. 360Dx. Cue health to lay off 170 people. 2022. <https://www.360dx.com/business-news/cue-health-lay-170-people>. Accessed 14 Aug 2022.
 154. 360Dx. PerkinElmer, siemens healthineers, SummerBio lay off workers, close facilities. 2022. <https://www.360dx.com/business-news/perkinelmer-siemens-healthineers-summerbio-lay-workers-close-facilities>. Accessed 14 Aug 2022.
 155. W N. The causation of pulmonary consumption. *Science.* 1886;7:86–8.
 156. Yerlikaya S, Broger T, MacLean E, Pai M, Denkinge CM. A tuberculosis biomarker database: the key to novel TB diagnostics. *Int J Infect Dis.* 2017;1:253–7.
 157. Pai NP, Vadnais C, Denkinge C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. *PLoS Med.* 2012;9:e1001306.